Topics

Articles

Specialty drug market access reality check

Enough already with REMS abuse in generic drug development

The keys to a successful and impactful partnership: A case study

The biologics development and approval process for pharmaceutical companies around the world is typically long and complex, which increases the risk of inaccurately forecasting demand

Dealing with biologics production uncertainty

Serialization’s interface between the plant floor, the enterprise and the world

Sharing clinical data—EvGen—will improve both drug development and health outcomes analysis

Laying the foundation for a national system for evidence generation

Strengthening healthcare and pharmaceutical supply chains is critical for healthcare resiliency

Specialty pharma becomes 'hub enabled'

Managing partner at Numerof & Associates.

A new, market-driven model of drug development and commercialization is appearing*

Bringing value to healthcare: practical steps for getting to a market-based model

Looking at 'cost' and 'value' under different evaluation processes

Opinion